|
Dr. Leslie Patmore is currently Managing Director of Aptuit Consulting Inc., the consulting division of Aptuit, a global drug development services company. Areas of consulting include drug development strategy, execution and safety assessment with particular expertise in QT prolongation. Until October 2005, Dr. Patmore was Vice President of the Preclinical Sciences and Pharmaceutical Analysis operations at Quintiles’ European pharmaceutical development centre in Edinburgh and worked for Quintiles for 10 years in various management positions. Dr Patmore has a B.Sc. and Ph.D. in Physiology and Biophysics and over 25 years of experience in pharmaceutical research and development. Previously at Syntex Pharmaceuticals for 15 years and with Roche briefly following the acquisition of Syntex in 1995, he has held positions in discovery research, safety assessment and as a leader of drug development programs. Actively involved in basic science and pharmaceutical R&D scientific societies, Dr. Patmore is a regular speaker at international opinion forming conferences and has particular interests in targets for new therapeutic entities and safety of drugs relating to proarrhythmic risk. Dr. Patmore holds an Honorary Research Fellowship in the Department of Medicine at Edinburgh University and serves as a Board Director of the Safety Pharmacology Society. | 